Recent surge of mucormycosis in COVID-19 patients: clinicians’ perspective from systems genomics

Sudhir Mehta1, *, Krishna Mohan Medicherla2, 4, Ayyagari Subramanyam4, PB Kavi Kishor3, 4, Prashanth Suravajhala2, 4, 5, *

1Department of General Medicine, SMS Medical College and Hospitals, Jaipur 302004, Rajasthan, India. 2Department of Biotechnology and Bioinformatics, Birla Institute of Scientific Research, Jaipur 302001, Rajasthan, India. 3Department of Biotechnology, Vignan’s Foundation for Science, Technology and Research, Vadlamudi, Guntur 522213, Andhra Pradesh, India. 4Bioclues.org, India. 5Amrita School of Biotechnology, Amrita Vishwavidyapeetham, Clappana PO, Kerala. 690525, India. *Correspondence: prash@bioclues.org, sudhirm02@gmail.com

Mucormycosis has been largely associated with COVID-19 patients. With the growing number of cases, there is an immediate need to understand the treatment regimen for COVID-19 which could predispose to mucormycosis infection. The authors have highlighted the points from clinicians’ perspective.

Mehta S, Medicherla KM, Subramanyam A, Kishor PBK, Suravajhala P(2022) Recent surge of mucormycosis in COVID-19 patients: clinicians’ perspective from systems genomics. MycoAsia 2022/04.